Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]).
Geyer CE Jr, Blum JL, Yothers G, Asmar L, Flynn PJ, Robert NJ, Hopkins JO, O'Shaughnessy JA, Rastogi P, Puhalla SL, Hilton CJ, Dang CT, Gómez HL, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Colangelo LH, Swain SM, Mamounas EP, Wolmark N. Geyer CE Jr, et al. Among authors: vukelja sj. J Clin Oncol. 2024 Apr 20;42(12):1344-1349. doi: 10.1200/JCO.23.01428. Epub 2024 Feb 9. J Clin Oncol. 2024. PMID: 38335467
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D; SOLAR-1 Study Group. André F, et al. N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904. N Engl J Med. 2019. PMID: 31091374 Clinical Trial.
Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
O'Shaughnessy J, Sousa S, Cruz J, Fallowfield L, Auvinen P, Pulido C, Cvetanovic A, Wilks S, Ribeiro L, Burotto M, Klingbiel D, Messeri D, Alexandrou A, Trask P, Fredriksson J, Machackova Z, Stamatovic L; PHranceSCa study group. O'Shaughnessy J, et al. Eur J Cancer. 2021 Jul;152:223-232. doi: 10.1016/j.ejca.2021.03.047. Epub 2021 Jun 16. Eur J Cancer. 2021. PMID: 34147014 Free article. Clinical Trial.
Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients.
Paul D, Vukelja SJ, Ann Holmes F, Blum JL, McIntyre KJ, Lindquist DL, Osborne CR, Sanchez IJ, Goldschmidt JH, Wang Y, Asmar L, Strauss L, O'Shaughnessy J. Paul D, et al. Among authors: vukelja sj. NPJ Breast Cancer. 2019 Oct 28;5:36. doi: 10.1038/s41523-019-0132-8. eCollection 2019. NPJ Breast Cancer. 2019. PMID: 31667338 Free PMC article.
Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer.
Holmes FA, Hellerstedt BA, Pippen JE Jr, Vukelja SJ, Collea RP, Kocs DM, Blum JL, McIntyre KJ, Barve MA, Brooks BD, Osborne CR, Wang Y, Asmar L, O'Shaughnessy J. Holmes FA, et al. Among authors: vukelja sj. Cancer Med. 2018 Jun;7(6):2288-2298. doi: 10.1002/cam4.1472. Epub 2018 Mar 26. Cancer Med. 2018. PMID: 29582557 Free PMC article. Clinical Trial.
Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer.
Osborne C, Challagalla JD, Eisenbeis CF, Holmes FA, Neubauer MA, Koutrelakos NW, Taboada CA, Vukelja SJ, Wilks ST, Allison MA, Reddy P, Sedlacek S, Wang Y, Asmar L, O'Shaughnessy J. Osborne C, et al. Among authors: vukelja sj. Clin Breast Cancer. 2018 Feb;18(1):e89-e95. doi: 10.1016/j.clbc.2017.07.002. Epub 2017 Jul 10. Clin Breast Cancer. 2018. PMID: 28779904 Free article. Clinical Trial.
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA, Robert NJ, Hopkins JO, O'Shaughnessy JA, Dang CT, Gómez HL, Fehrenbacher L, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Jeong JH, Colangelo LH, Swain SM, Mamounas EP, Jones SE, Wolmark N. Blum JL, et al. Among authors: vukelja sj. J Clin Oncol. 2017 Aug 10;35(23):2647-2655. doi: 10.1200/JCO.2016.71.4147. Epub 2017 Apr 11. J Clin Oncol. 2017. PMID: 28398846 Free PMC article. Clinical Trial.
Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole.
Krekow LK, Hellerstedt BA, Collea RP, Papish S, Diggikar SM, Resta R, Vukelja SJ, Holmes FA, Reddy PK, Asmar L, Wang Y, Fox PS, Peck SR, O'Shaughnessy J. Krekow LK, et al. Among authors: vukelja sj. J Clin Oncol. 2016 May 10;34(14):1594-600. doi: 10.1200/JCO.2015.62.2985. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884554 Clinical Trial.
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.
Jones SE, Collea R, Paul D, Sedlacek S, Favret AM, Gore I Jr, Lindquist DL, Holmes FA, Allison MAK, Brooks BD, Portillo RM, Vukelja SJ, Steinberg MS, Stokoe C, Crockett MW, Wang Y, Asmar L, Robert NJ, O'Shaughnessy J. Jones SE, et al. Among authors: vukelja sj. Lancet Oncol. 2013 Oct;14(11):1121-1128. doi: 10.1016/S1470-2045(13)70384-X. Epub 2013 Sep 3. Lancet Oncol. 2013. PMID: 24007746 Clinical Trial.
59 results